Mimedx Group, INC Form 4 insider transactions

MIMEDX Group, Inc. Director Cato T. Laurencin was granted 28,609 shares of common stock as part of an annual restricted stock award for non-employee directors.

MIMEDX Group, Inc. Director Tiffany Olson acquired 28,609 shares of common stock at $6.47 per share as part of an annual restricted stock grant, increasing her total beneficial ownership to 57,597 shares.

MIMEDX Group, Inc. Director Dorothy Puhy was granted 28,609 shares of common stock as part of her annual restricted stock compensation, effective June 18, 2025.

William Frank Hulse IV, General Counsel and CAO of MiMedx Group, sold shares to cover tax liabilities upon the vesting of restricted stock units.

MiMedx Group's CEO, Joseph Capper, purchased 200,000 shares of common stock at $6.34 per share on May 2, 2025.

William Frank Hulse IV, General Counsel and CAO of MiMedx Group, sold 8,876 shares of common stock on April 23, 2025, to cover tax liabilities upon vesting of restricted stock units.

William Frank Hulse IV, General Counsel and CAO of MiMedx Group, sold shares to cover tax liabilities upon the vesting of restricted stock units.

Chief Commercial Officer Kimberly Maersk-Moller of MIMEDX Group, Inc. reports disposition of shares to cover tax obligations.

Kimberly Maersk-Moller, Chief Commercial Officer of MiMedx Group, sold 1,759 shares of common stock on March 17, 2025, to cover tax withholding obligations related to vesting restricted stock units.

William Frank Hulse IV, General Counsel and CAO of MiMedx Group, sold shares to cover tax withholding liabilities related to vesting performance and restricted stock units.

Kimberly Maersk-Moller, Chief Commercial Officer of MiMedx Group, sold 4,106 shares of common stock on March 13, 2025, to cover tax obligations related to vesting restricted stock units.

William Frank Hulse IV, General Counsel and CAO of MiMedx Group, sold 81,446 shares of common stock at an average price of $7.80 and corrected a typographical error regarding the exercise price of stock options granted on March 3, 2025.

Kimberly Maersk-Moller, Chief Commercial Officer of MiMedx Group, reports the sale of shares to cover tax obligations and the acquisition of restricted stock and stock options.

Ricci S. Whitlow, Chief Operating Officer of MiMedx Group, received grants of restricted stock and stock options on March 3, 2025.

William Frank Hulse IV, General Counsel and CAO of MiMedx Group, Inc., reports acquisition of shares through vesting of performance stock units and grant of restricted stock, along with stock options.

Doug Rice, CFO of MiMedx Group, reports the acquisition of common stock and stock options, increasing his beneficial ownership in the company.

CEO Joseph Capper reports acquisition of restricted stock and stock options, along with adjustments to his holdings in MiMedx Group, Inc.

Ricci S. Whitlow, Chief Operating Officer of MiMedx Group, Inc., sold 61,420 shares of common stock on February 13, 2025, to cover tax obligations related to vesting restricted stock units.

MiMedx Group's Chief Commercial Officer, Kimberly Maersk-Moller, was granted 125,581 shares of restricted stock and disposed of 267,382 shares.

Doug Rice, CFO of MiMedx Group, reports the withholding of 12,749 common stock shares to cover tax liabilities upon vesting of restricted stock units on July 8, 2024.

Director Cato T. Laurencin acquired 23,190 shares of MiMedx Group, Inc. common stock on June 5, 2024, as part of an annual restricted stock grant.

Director James L. Bierman acquired 23,190 shares of MiMedx Group, Inc. common stock at a price of $7.26 per share on June 5, 2024, as part of an annual restricted stock grant.

K. Todd Newton, a director of MiMedx Group, Inc., acquired 23,190 shares of common stock through an annual restricted stock grant.

Director M Kathleen Behrens acquired 23,190 shares of Mimedx Group, Inc. common stock at $7.26 per share on June 5, 2024, increasing her direct holdings to 184,162 shares.

Director William Hawkins acquired 23,190 shares of MiMedx Group, Inc. common stock at $7.26 per share as part of an annual restricted stock grant.

Director Tiffany Olson acquired 28,988 shares of MiMedx Group, Inc. common stock on June 5, 2024, as part of an annual restricted stock grant.

Director Dorothy Puhy received 28,988 shares of MiMedx Group, Inc. common stock as part of an annual restricted stock grant.

William Frank Hulse IV, General Counsel and CAO of MiMedx Group, sold 8,896 shares of common stock on May 8, 2024, to cover tax liabilities upon vesting of restricted stock units.

William Frank Hulse IV, General Counsel and CAO of MiMedx Group, sold 8,896 shares to cover tax liabilities arising from vesting restricted stock units.

William Frank Hulse IV, General Counsel and CAO of MiMedx Group, reports disposition of shares to cover tax obligations upon vesting of restricted stock units.